Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.
| Autor: | Szafoni S; Students' Scientific Circle in Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland., Gręblowski P; Students' Scientific Circle in Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland., Grabowska K; Students' Scientific Circle in Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland., Więckiewicz G; Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in psychiatry [Front Psychiatry] 2024 Jun 11; Vol. 15, pp. 1406888. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024). |
| DOI: | 10.3389/fpsyt.2024.1406888 |
| Abstrakt: | Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As a result, several studies are currently being conducted to find effective alternatives to traditional therapies. One of these alternatives is psilocybin, a psychedelic substance that has been tested in clinical trials as an adjunct to psychotherapy. These studies focus on patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD) and substance use disorder (SUD), particularly alcohol and nicotine dependence. This article looks at the current understanding of psilocybin, including data from clinical trials conducted, psilocybin's mechanism of action, its safety and the level of risk associated with it. Competing Interests: GW served as a member of Advisory Board of: Angelini Pharma Polska, received honoraria for lectures from: Canopy Growth Polska and Angelini Pharma Polska, support for attending meetings from: Angelini Pharma Polska, Apotex Poland/Aurovitas Pharma Polska and Lek-AM. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Szafoni, Gręblowski, Grabowska and Więckiewicz.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|